
BLRX
Healthcare · Biotechnology · $6.5M market cap
$1.30-0.05 (-3.7%)Nov 13, 4:00 PM EST
Next report
Before the open
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -327.8% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 23, 2026 · upcoming | Before the open | -0.38 | — | — |
| Aug 31, 2026 | Before the open | -0.30 | -0.77 | -156.7% |
| May 27, 2026 | Before the open | -1.04 | -0.58 | +44.0% |
| Mar 23, 2026 | Time not confirmed | -0.77 | 0.00 | +100.0% |
| Nov 24, 2025 | Before the open | -0.54 | -0.23 | +58.2% |
| Aug 14, 2025 | Before the open | -0.53 | -1.02 | -92.2% |
| May 27, 2025 | Before the open | -1.06 | -1.50 | -41.6% |
| Mar 26, 2025 | Time not confirmed | -0.03 | 0.00 | +100.0% |
| Nov 25, 2024 | Before the open | -4.40 | -0.07 | +98.3% |
| Aug 15, 2024 | Before the open | -5.60 | 0.01 | +100.1% |
| May 28, 2024 | Before the open | -11.60 | -0.01 | +99.9% |
| Mar 28, 2024 | After the close | -0.16 | -0.15 | +6.3% |
| Nov 20, 2023 | Before the open | -8.40 |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of…
| -12.00 |
| -42.9% |
| Aug 30, 2023 | Before the open | -6.80 | -12.00 | -76.5% |
| May 24, 2023 | Before the open | -5.60 | -6.00 | -7.1% |
| Mar 22, 2023 | Time not confirmed | -0.09 | -0.09 | 0.0% |
| Nov 15, 2022 | Before the open | -4.53 | -6.00 | -32.5% |
| Aug 16, 2022 | Before the open | -5.20 | -6.00 | -15.4% |
| May 11, 2022 | Before the open | -6.00 | -0.40 | +93.3% |
| Mar 16, 2022 | Before the open | -0.14 | -0.10 | +28.6% |
| Nov 18, 2021 | Before the open | -5.00 | -6.00 | -20.0% |
| Aug 18, 2021 | Before the open | -4.60 | -6.00 | -30.4% |
| May 26, 2021 | Before the open | -7.47 | -0.80 | +89.3% |
| Feb 23, 2021 | Before the open | -9.73 | -24.00 | -146.7% |
| Nov 23, 2020 | Before the open | -13.60 | -12.00 | +11.8% |
| Aug 6, 2020 | Before the open | -24.00 | -18.00 | +25.0% |
| May 20, 2020 | Before the open | -33.00 | -24.00 | +27.3% |
| Mar 12, 2020 | After the close | -0.66 | -0.90 | -36.4% |
| Nov 11, 2019 | Before the open | -2.00 | -1.20 | +40.0% |
| Aug 6, 2019 | Before the open | -24.67 | -24.00 | +2.7% |
| May 14, 2019 | Before the open | -30.00 | -30.00 | 0.0% |
| Mar 28, 2019 | After the close | -1.39 | -0.60 | +56.8% |
| Nov 8, 2018 | Before the open | -33.00 | -36.00 | -9.1% |
| Aug 13, 2018 | Before the open | -36.00 | -30.00 | +16.7% |
| May 22, 2018 | Before the open | -42.00 | -36.00 | +14.3% |
| Mar 6, 2018 | Before the open | -37.50 | -42.00 | -12.0% |